Pharvaris's experimental oral drug, deucrictibant, achieved an 83% reduction in hereditary angioedema (HAE) attack rates in its CHAPTER-3 Phase 3 study. Analyst firm Oppenheimer significantly increased its price target for Pharvaris to $75.00 from $50.00, reaffirming an "Outperform" rating. The positive clinical trial data and analyst confidence propelled Pharvaris's stock price, reaching a new 52-week high and boosting its market capitalization to approximately $2.64 billion.Pharvaris (NASDAQ: PHVS) is a ...